gdc
FDA Approvals, News & UpdatesNewsworthy

Actemra First Treatment Approved for CAR T-Cell–Induced Cytokine-Release Syndrome

December 2017 Vol 3 No 6

On August 30, 2017, in association with the approval of the first CAR T-cell therapy (Kymriah), the FDA approved a new use for Actemra (tocilizumab; from Genentech), a humanized IL-6 receptor antagonist, for CAR T-cell–induced severe or life-threatening cytokine-release syndrome in patients older than 2. Cytokine-release syndrome can be caused by immune-cell therapy, such as CAR T-cell therapy.

This approval was based on a clinical trial showing the benefits of Actemra in patients with cytokine-release syndrome. Overall, 69% of patients had a response to Actemra within 14 days of treatment, meaning that the cytokine-release syndrome was resolved.

Serious side effects with Actemra include risk of serious infections and certain cancers, tears in the stomach, thrombocytopenia, neutropenia, hepatitis B infection, serious allergic reactions, and central nervous system problems.

Share this:

Recommended For You
FDA Approvals, News & UpdatesBreast Cancer
Verzenio First CDK4/6 Approved with Endocrine Therapy for Adjuvant Treatment of Early Breast Cancer
In October 2021, the FDA approved the combination of Verzenio (abemaciclib), a CDK 4/6 inhibitor, plus endocrine therapy for adjuvant treatment (after surgery) of adults with HR-positive, HER2-negative, node-positive, early breast cancer that is at high risk of recurrence.
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination Approved for Multiple Myeloma
In November 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase) plus Kyprolis (carfilzomib) and dexamethasone for adults with relapsed or refractory multiple myeloma who have received previous therapy.
FDA Approvals, News & UpdatesKidney Cancer
Keytruda FDA Approved for Adjuvant Treatment of Kidney Cancer
In November 2021, the FDA approved a new indication for the immunotherapy Keytruda (pembrolizumab) for adjuvant treatment (after surgery) of patients with renal-cell carcinoma that is at intermediate-high or high risk for recurrence.
FDA Approvals, News & UpdatesCervical Cancer
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
In October 2021, the FDA approved the immunotherapy Keytruda (pembrolizumab), in combination with chemotherapy and with or without Avastin (bevacizumab), for patients with persistent, recurrent, or metastatic cervical cancer and PD-L1 expression.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest